Recently, it has been demonstrated that the administration of cysteamine, a known inhibitor of TG2, promotes a general amelioration of the disease in CF patients by reducing inflammation and restoring the CFTR function [73,74]. This evidence concerns the gene CFTR and cystic fibrosis.